SCHEMBL5397222

SCHEMBL5397222

COc1ccc(CN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2cccc3ccccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.53
CHRNA4 P43681 1/20 0.53
HDAC1 Q13547 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
PTPN1 P18031 1/20 0.48
KCNK3 O14649 2/20 0.47
KCNK5 O95279 1/20 0.47
KCNA5 P22460 1/20 0.47
KCNK17 Q96T54 1/20 0.47
KCNK9 Q9NPC2 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
LPAR1 Q92633 2/20 0.44
KCNH2 Q12809 1/20 0.44
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402292 0.92 PTPN1 (0.52) CHRNB2CHRNA4PTPN1KCNK3KCNK5
SCHEMBL5416837 0.91 CHRNB2 (0.60) CHRNB2CHRNA4HDAC1HDAC6RAB9A
SCHEMBL5403175 0.90 HDAC1 (0.59) HDAC1HDAC6RAB9ATDP1LPAR1
SCHEMBL5397479 0.89 HDAC1 (0.61) CHRNB2CHRNA4HDAC1HDAC6RAB9A
SCHEMBL5407093 0.89 HDAC1 (0.61) CHRNB2CHRNA4HDAC1HDAC6RAB9A
SCHEMBL5397765 0.88 HDAC1 (0.49) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5403587 0.88 CHRNB2 (0.55) CHRNB2CHRNA4HDAC1HDAC6KCNK3
SCHEMBL5394243 0.88 TAS1R3 (0.52) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5409503 0.88 MAPK8 (0.51) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5401992 0.88 KCNK3 (0.55) HDAC1HDAC6KCNK3KCNK5KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB CHRNB2 857/4885CHRNA4 1750/4885HDAC1 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.